Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, safety and immunogenicity of BI 695501 versus Humira in rheumatoid arthritis
2012-002945-40Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab-adbm in rheumatoid arthritis (RA) (2 arms), sponsored by Boehringer Ingelheim. Started Apr 2014; status: completed.
02
Drugs
adalimumab-adbm
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-002945-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002945-40.